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Abstract
Background: Emerging evidence indicates that, similarly to what happens for peripheral macrophages, microglia can
express different phenotypes depending on microenvironmental signals. In spite of the large literature on inflammation
after ischemia, information on M/M phenotype marker expression, their colocalization and temporal evolution in the
injured brain is lacking. The present study investigates the presence of microglia/macrophage phenotype markers, their
temporal expression, whether they are concomitantly expressed by the same subpopulation, or they are expressed at
distinct phases or locations in relation to the ischemic lesion.
Methods: Volume of ischemic lesion, neuronal counts and TUNEL staining were assessed in C57Bl/6 mice at 6-12-24-48
h and 7d after permanent occlusion of the middle cerebral artery. At the same time points, the expression, distribution
in the lesioned area, association with a definite morphology and coexpression of the microglia/macrophage markers
CD11b, CD45, CD68, Ym1, CD206 were assessed by immunostaining and confocal microscopy.
Results: The results show that: 1) the ischemic lesion induces the expression of selected microglia/macrophage
markers that develop over time, each with a specific pattern; 2) each marker has a given localization in the lesioned
area with no apparent changes during time, with the exception of CD68 that is confined in the border zone of the
lesion at early times but it greatly increases and invades the ischemic core at 7d; 3) while CD68 is expressed in both
ramified and globular CD11b cells, Ym1 and CD206 are exclusively expressed by globular CD11b cells.
Conclusions: These data show that the ischemic lesion is accompanied by activation of specific microglia/
macrophage phenotype that presents distinctive spatial and temporal features. These different states of microglia/
macrophages reflect the complexity of these cells and their ability to differentiate towards a multitude of
phenotypes depending on the surrounding micro-environmental signals that can change over time. The data
presented in this study provide a basis for understanding this complex response and for developing strategies
resulting in promotion of a protective inflammatory phenotype.
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Background
Microglia, the major cellular contributors to post-injury
inflammation, have the potential to act as markers of
disease onset and progression and to contribute to neu-
rological outcome of acute brain injury. They are nor-
mally present in the healthy brain where they actively
survey their surrounding parenchyma by protracting and
retracting their processes and they are endowed with
the capacity to rapidly respond to injury or alterations
in their microenvironment [1-3]. After acute brain
injury, these resident cells are rapidly activated and
undergo dramatic morphological and phenotypic
changes. Typical morphological changes associated with
microglia activation include thickening of ramifications
and of cell bodies followed by acquisition of a rounded
amoeboid shape. This intrinsic response is associated to
recruitment of blood-born macrophages which migrate
into the injured brain parenchyma [4,5]. This process is
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and production of mediators that build up and maintain
the inflammatory response of the brain tissue. Activated
microglia and recruited macrophages (which are antige-
nically not distinguishable, henceforth referred to as M/
M), can affect neuronal function and promote neuro-
toxicity through the release of several harmful compo-
nents such as IL-1b,T N F - a, proteases and reactive
oxygen and nitrogen species [6,7]. On the other hand
they also possess protective qualities and promote neu-
rogenesis and lesion repair [8-10]. Indeed, microglia
have been proposed to be beneficial by several mechan-
isms including glutamate uptake [11] removal of cell
debris [12] and production of neurotrophic factors such
as IGF-1 [13], GDNF [14] and BDNF [15,16].
Studies addressing phenotypic changes occurring in
macrophages in peripheral inflammation and immunity
have shown that these cells can undergo different forms
of polarized activation. One is the classic or M1 activa-
tion, characterized by high capacity to present antigen,
high production of NO and ROS and of proinflamma-
tory cytokines. M1 cells act as potent effectors that kill
micro-organisms and tumor cells, drive the inflamma-
tory response and may mediate detrimental effects on
neural cells. The second phenotype (M2) is an alterna-
tive apparently beneficial activation state, more related
to a fine tuning of inflammation, scavaging of debris,
promotion of angiogenesis, tissue remodeling and repair.
Specific environmental signals are able to induce these
different polarization states [17]. A similar possibility
has been also recently raised for microglia, by showing
that these cells, under certain conditions, can indeed be
pushed to both extremes of the M1 and M2 differentia-
tion spectrum [16,18]. More studies are needed to sub-
stantiate these observations.
In this frame the present study aims at getting insight
on previously unexplored aspects of microglia phenotype
changes induced by cerebral ischemia, namely, the pre-
s e n c eo fs p e c i f i cp h e n o t y p emarkers, their temporal
expression, whether or not they are concomitantly
expressed by the same subpopulation, whether they are
expressed at distinct phases or locations in relation to the
ischemic lesion. We focussed on a few molecules that are
known to be expressed by macrophages in peripheral
inflammation and that have been associated to different
functions. They include: CD11b, a marker of M/M acti-
vation/recruitment, CD45 expressed on all nucleated
hematopoietic cells [19], CD68 a marker of active phago-
cytosis, Ym1 a secretory protein that binds heparin and
heparin sulphate and CD206 a C-type lectin carbohydrate
binding protein, both of them expressed by alternatively
activated macrophages and associated to recovery and
function restoration [20,21].
Methods
Animals
Male C57Bl/6 mice (10-week old, 20-25 g, Harlan
Laboratories, Italy) were used. Procedures involving ani-
mals and their care are conducted in conformity with the
institutional guidelines (Quality Management System
Certificate - UNI EN ISO 9001:2008 - Reg. N° 8576-A)
that are in compliance with national (D. Lvo. n. 116, 27
Gennaio 1992; Legge n° 413, 12 Ottobre 1993; Circolare
No. 8, 22 Aprile 1994; D.M. 29/09/95; D.M. 26/04/2000)
and international (EEC Council Directive 86/609, OJ L
358, 1, Dec. 12, 1987; Guide for the Care and Use of
Laboratory Animals, U.S. National Research Council,
1996) laws and policies. Before beginning any procedure,
mice were housed for at least 1 week in their home cages
at a constant temperature, with a 12 hour light-dark
cycle, and ad libitum access to food and water in a selec-
tive pathogen-free (SPF) vivarium.
Focal cerebral ischemia
Permanent ischemia was obtained by permanent middle
cerebral artery occlusion (pMCAO) [22,23]. Briefly, mice
were anesthetized with Equitensin (pentobarbital 39 mM,
chloral hydrate 256 mM, MgSO4 86 mM, ethanol 10%
v/v, propyleneglycol 39.6% v/v) 100 μl/mouse administered
by intraperitoneal (i.p.) injection. A vertical midline inci-
sion was made between the right orbit and tragus. The
temporal muscle was excised, and the right MCA was
exposed through a small burr hole in the left temporal
bone. The dura mater was cut with a fine needle, and the
MCA permanently occluded by electrocoagulation just
proximal to the origin of the olfactory branch. Intraopera-
tive rectal temperature was kept at 37.0 ± 0.5°C using a
heating pad (LSI Letica). Mortality rate was 8.5%. Sham-
operated mice received identical anesthesia and surgical
procedure without artery occlusion.
Experimental design and blinding
Mice were assigned to surgery and experimental groups
with surgery distributed equally across cages and days. To
minimize the variability, all surgeries were performed by
the same investigator, blinded to the experimental groups.
All subsequent histological and immunohistological eva-
luations were also done by blinded investigators.
Brain transcardial perfusion
At selected time points mice were deeply anesthetized
with Equitensin (120 μl/mouse i.p.) and transcardially per-
fused with 20 ml of PBS, 0.1 mol/liter, pH 7.4, followed by
50 ml of chilled paraformaldehyde (4%) in PBS. After care-
fully removing the brains from the skull, they were trans-
ferred to 30% sucrose in PBS at 4°C overnight for
cryoprotection. The brains were then rapidly frozen by
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sealed into vials and stored at -70°C until use.
Quantification of infarct size
For lesion size determination, 20-μm coronal brain cryo-
sections were cut serially at 320-μm intervals and stained
with Cresyl Violet [8]. On each slice, the infarcted area
was assessed blindly and delineated by the relative pale-
ness of histological staining tracing the area on a video
screen. The infarcted area and the percentage of brain
swelling for edema correction were determined by sub-
t r a c t i n gt h ea r e ao ft h eh e a l t h yt i s s u ei nt h ei p s i l a t e r a l
hemisphere from the area of the contralateral hemisphere
on each section [24,25]. Infarct volumes were calculated
by the integration of infarcted areas on each brain slice
as quantified with computer- assisted image analyzer and
calculated by Analytical Image System (Imaging Research
Inc., Brock University, St. Catharines, Ontario, Canada).
Slice selection and quantitative analysis
Three brain coronal sections per mouse (+1.54, +0.50 and
- 0.94 mm from bregma, KBJ Franklin and G Paxinos, The
Mouse Brain in Stereotaxic Coordinates, Academic Press),
were used to quantify the stained area. On each slice, ana-
tomically defined cortical regions of interest were demar-
cated, corresponding to the primary motor cortex,
somatosensory cortex, insular cortex (granular, agranular)
and secondary somatosensory cortex, representing the
cortical regions involved in the largest lesion extension
observed at 24 h after ischemia. Field selection was per-
formed using a BX61 Olympus microscope equipped with
a motorized stage acquiring the same focal plan through-
out the samples [26]. For neuronal count, CD11b and
CD68 quantification fields at 40× magnification were
selected at 1.54 mm anterior to bregma (11 fields), at 0.50
mm anterior to bregma (11 fields) and at 0.94 mm poster-
ior to bregma (11 fields). The first raw of fields was posi-
tioned at the lesion edge, spacing each field by 572.5 μm
(distance between centres of the fields). Further raws of
fields were positioned distanced by 389.3 μm each. For
TUNEL, CD45, Ym1 and CD206 twenty-four quantifica-
tion fields at 20× magnification were selected. Eight fields
per slice were selected and fields were separated by 572.5
μm (distance between centres of fields), while distance
between each raw was 389.3 μm. A schematic representa-
tion of the regions of interest and of the selected fields is
depicted in Figure 1.
Neuronal Count
Cresyl Violet stained brain sections were used for neuro-
nal count. Thirty-three fields at 40× were analyzed for
each mouse. The amount of neuronal loss was calculated
by pooling the number of stained neurons in the three
ipsilateral sections and expressed as percentage of those
in sham- operated animals. Fields were analyzed using
ImageJ software http://rsbweb.nih.gov/ij/ and segmenta-
tion was used to discriminate neurons from glia on the
basis of cell size.
TUNEL staining
To assess the presence of injured cells showing DNA
damage, terminal deoxynucleotidyl transferaseYmediated
dUTP nick end labeling (TUNEL) staining was per-
formed on 20-μm sections by in situ cell death detection
kit (Roche, Mannheim, Germany) according to the man-
ufacturer instructions, as previously described [27].
Figure 1 Slices selection and tissue sampling for neuronal counts and quantification of immunostained area. Fields for neuronal counts,
TUNEL evaluation and quantification of stained area were positioned within the ischemic territory at defined distances (see methods for details).
The regions sampled pertained to the ischemic territory (yellow) at the time points considered (6 h, 12 h, 24 h, 48 h and 7d).
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After staining, the sections were visualized using fluores-
cent microscopy (Olympus IX70 Olympus Tokyo,
Japan). Images of the area of interest were acquired
using AnalySIS software (Olympus, Tokyo, Japan). For
each mouse twenty-four fields at 20× were analyzed.
TUNEL-positive cells were counted using ImageJ soft-
ware http://rsbweb.nih.gov/ij/ and expressed as number
per mm
2 for subsequent statistical analysis [28].
Immunohistochemistry
Immunohistochemistry was performed on 20-μmb r a i n
coronal sections using anti-mouse CD11b (1:700, kindly
provided by Dr. Doni, [8] anti-mouse-CD45 (1:800, BD
Biosciences Pharmigen, San Jose, CA), anti-mouse CD68
(1:200, Serotec, Kidlington, UK), anti-mouse Ym1 (1:400,
Stem Cell Technologies, Vancouver, Canada), anti-mouse
CD206 (1:100, Serotec, Kidlington, UK). Positive cells were
stained by reaction with 3, 3 diaminobenzidine tetrahy-
drochloride (DAB, Vector laboratories, CA, USA). For
negative control staining, the primary antibodies were
omitted and no staining was observed. CD45-positive cells
displayed 2 morphologies: a leukocyte-like shape corre-
sponding to cells with a rounded cell body without
branches and high expression of CD45 (CD45
high), and a
microglia-like shape having a small cell body and several
branches and a fainter expression of CD45 (CD45
low)[ 2 2 ] .
Quantification was carried out on CD45
high cells. Immu-
nostained area for each marker was measured using ImageJ
software http://rsbweb.nih.gov/ij/ and expressed as positive
pixels/total assessed pixels and indicated as staining per-
centage area (as number per mm
2 for CD206) for subse-
quent statistical analysis [28].
Immunofluorescence and confocal analysis
Immunofluorescence was performed on 20-μm coronal
sections according to the previously described method
[22]. Primary antibodies used were: anti-mouse CD45
(1:800 or 1:1500); anti-mouse Ym1 (1:400, Stem Cell
Technologies, Vancouver, Canada), anti-mouse CD206
(1:100, Serotec, Kidlington, UK), anti-mouse CD11b
(1:30000, kindly provided by Dr. Doni), anti-mouse CD68
(1:200, Serotec, Kidlington, UK), anti-mouse NeuN (1:250,
Millipore, Billerica, MA, USA). Fluorconjugated secondary
antibodies used were: Alexa 546 anti-rat, Alexa 594 anti-
rabbit, Alexa 488 anti-mouse (all 1:500, Invitrogen, Carls-
bad, CA). Biotinilated anti-rat antibodies (1:200, Vector
Laboratories, Burlingame, CA) were also used followed by
fluorescent signal coupling with streptavidine TSA ampli-
fication kit (cyanine 5, Perkin Elmer, MA, USA). Similarly
to what reported for immunohistochemistry DAB staining,
also in this case we considered only cell displaying CD45
rounded morphology (CD45
high, [22]). Appropriate nega-
tive controls without the primary antibodies were
performed. None of the immunofluorescence reactions
revealed unspecific fluorescent signal in the negative con-
trols. Immunofluorescence was acquired using a scanning
sequential mode to avoid bleed-through effects by an IX81
microscope equipped with a confocal scan unit FV500
with 3 laser lines: Ar-Kr (488 nm), He-Ne red (646 nm),
and He-Ne green (532 nm) (Olympus, Tokyo, Japan) and
aU Vd i o d e .
Two main areas of interest were considered, namely
ischemic core and border zone [29] at both 24 h and 7d
after pMCAo Three-dimensional images were acquired
over a 10 μmz - a x i sw i t ha0 . 2 3μms t e ps i z ea n dp r o -
cessed using Imaris software (Bitplane, Zurich, Switzer-
land) and Photoshop cs2 (Adobe Systems Europe Ltd).
Statistical analysis
Statistical power (1-b) was assessed as post-hoc analysis by
means of G*Power [30]. Statistical analysis was performed
using standard software packages GraphPad Prism
(GraphPad Software Inc., San Diego, CA, USA, version
4.0). All data are presented as mean and standard devia-
tion (sd). The comparison between groups was performed
using One-way ANOVA followed by appropriate post hoc
test. p-values lower than 0.05 were considered statistically
significant.
Results
Histopathological findings at different time points from
pMCAO
pMCAO induced an infarcted area in the ipsilateral cortex
(Figure 2A) as expected [22,23]. The lesion, evaluated as
relative paleness of cresyl violet staining and corrected for
edema, at 6 h, 12 h, 24 h, 48 h and 7d, had a volume of
12.5 mm
3 ±5 . 8 ,1 2 . 4m m
3 ± 5.7, 23.8 mm
3 ± 5.1, 22.1
mm
3 ± 3.3 and 9.6 mm
3 ± 4.7, respectively (Figure 2B).
Cortex, the brain area involved in the ischemic lesion
was considered for neuronal count (Figure 2C). Six hours
after ischemia, neuronal count performed in the ipsilateral
cortex revealed a significant cell loss when compared to
the corresponding area in the sham-operated group
(84.9%). Neuronal counts progressively but slowly
decreased reaching 64.9% at 7d. No significant difference
was found between ispilateral and contralateral side in
sham-operated animals (data not shown).
At 6 h after pMCAO rare TUNEL-positive cells were
present in the injuried cortex indicating the presence of
few dying cells (30.2 ± 14.2, expressed as cell density per
mm
2, Figure 2D). Number of dying cells progressively
increased at 12, 24 and 48 h post ischemia (278.6 ± 51.1,
589.7 ± 77.3 and 708.8 ± 30.2, respectively). Seven days
after ischemia still several TUNEL-positive cells were pre-
sent (343.6 ± 120.0) indicating the persistence of dying
cells at this time point. Positive TUNEL staining was not
apparent in any sham-operated mice at any time points.
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CD68, Ym1, CD206
The M/M markers expression was analyzed within the
ischemic area based on the tissue sampling represented
in Figure 1. At each time point, the sampled cortical area
pertained to the ischemic territory, being the number of
neurons in this region decreased compared to sham ani-
mals at every time points (Figure 2C).
CD11b, a constitutive marker of microglia and macro-
phages was expressed at every time point considered as
well as in sham-operated mice (5.6 ± 1.9, percent of
stained area). Starting from 6 h the immunoreactivity
increased and remained elevated at every subsequent time
point considered, with no major differences throughout
the experimental groups (9.5 ± 1.5, 11.7 ± 1.6, 10.1 ± 1.7,
13.1 ± 2.8, 13.0 ± 0.1, respectively at 6 h, 12 h, 24 h, 48 h
and 7d, Figure 3B).
Outside the lesion, CD11b staining revealed thin ramifi-
cations and small soma (Figure 3A/C). CD11b immunor-
eactivity was associated with a different morphology in
relation to the cell localization in the lesioned area. Two
main areas were identified, namely a lesion border show-
ing CD11b+ highly ramified cells (Figure 3A/D) and an
ischemic core showing both CD11b+ ameboid cells and
cells with hypertrophic soma endowed with thick branches
(Figure 3A/E).
No CD45-positive cells (CD45
high cells, see methods,
Figure 3F) could be observed in sham-operated mice
and in the contralateral hemisphere of ischemic mice.
Six hours after ischemia these cells were clearly visible
in the area considered (0.4 ± 0.2 percent of stained
area). The immunoreactivity was further increased 12
and 24 h after ischemia (0.6 ± 0.2 and 1.1 ± 0.3, respec-
tively). No further increase could be observed at 48 h
(1.1 ± 0.4). CD45 staining was still present at 7d (0.9 ±
0.4, Figure 3F).
CD68 immunoreactivity was undetectable in sham-
operated mice and appeared 6 h after ischemia (0.3 ± 0.2
percent of stained area). It progressively increased at
every time point considered (0.6 ± 0.2 at 12 h; 1.7 ± 0.2
at 24 h; 3.7 ± 0.8 at 48 h). Notably, a dramatic increase in
the CD68 stained area could be observed at 7d (7.4 ± 1.4,
Figure 3G).
Ym1 immunoreactivity was detectable starting from 12
h (0.04 ± 0.02 percent of stained area). This marker was
maximally expressed at 24 h (0.84 ± 0.16) and markedly
decreased at later time points (0.37 ± 0.10 at 48 h and
0.23 ± 0.15 at 7d, Figure 3H).
Figure 2 Histopathological findings at different time points from pMCAO. A: representative brain coronal sections obtained 24 h after
pMCAO. Pale demarcated areas depict the ischemic lesion. Quantification of ischemic volume (B), neuronal counts (data obtained from the
mean of 33 frames/mouse and expressed as % of sham groups, C) and TUNEL-positive cells (D) in the cortex of sham and ischemic mice at
different times after pMCAO. Data are reported as mean+sd, n = 8. *p < 0.05, **p < 0.01, ***p < 0.001 versus sham; °p < 0.05, °°p < 0.01, °°°p <
0.001 versus 6 h, Bonferroni’s Multiple Comparison Test.
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Page 5 of 19Figure 3 Immunohistochemical analysis and quantification of microglial markers: CD11b, CD45, CD68, Ym1, CD206. A: representative
micrographs of CD11b immunostaining in the injured cortex at 24 hours after pMCAo. CD11b-positive cells display different morphology
depending on their localization in the ischemic area (C: outside the lesion, D: border zone, E: ischemic core). B: quantification of CD11b
immunostaining at different times after pMCAo. Representative micrographs of CD45 (F), CD68 (G), Ym1 (H), CD206 (I) immunoreactivity at 24
hours after ischemia, and related quantifications at different times after pMCAO (Bar 10 μm). Data are expressed as mean+sd of 33 frames/
mouse (24 frames/mouse for CD45, TUNEL, CD206), n = 8. One way Anova: p < 0.0001. *p < 0.05, **p < 0.01 vs sham; °°p < 0.01, °°°p < 0.001 vs
6 h (12 h for Ym1). Bonferroni’s Multiple Comparison Test.
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mice (7.3 ± 0.9 cell/mm
2). They could be observed 6 h
after pMCAO (12.2 ± 6.2) and significantly increased
progressively up to 24 h (23.6 ± 5.3 at 12 h and 40.0 ±
14.9 at 24 h). A significant number of CD206 positive
c e l l sw a ss t i l lp r e s e n ta t4 8h( 3 0 . 5±1 0 . 5 )a n da t7 d
(32.7 ± 8.8, Figure 3I).
Localization of M/M markers with respect to the lesion
Twenty-four hours after pMCAO, the immunoreactivity
for CD11b appeared to be evenly distributed in the
ischemic area, being present both in the lesion border
and in the ischemic core (Figure 4). At the same time
CD45 staining showed a similar distribution being
present throughout the entire ischemic area (Figure 4).
CD45 cells visible at 10× magnification (Figure 4) did
not reveal the presence of CD45
low cells (corresponding
to ramified microglia) appearing in the CD11b staining
microphotograph. Conversely CD68 appeared to be
mainly concentrated in the border zone, with rare cells
present in the ischemic core. Notably, at longer time
points (7d) along with the great increase of its expres-
sion (Figure 3G), CD68 appears both in the border and
in the core areas. Ym1 at 24 h after pMCAO appeared
exclusively expressed in the ischemic core, similarly to
CD206 (Figure 4). With the exception of CD68, all the
markers considered showed a similar distribution at
every time point (data not shown).
Figure 4 Distribution of the selected M/M markers inside the ischemic lesion at 24 h from the injury. Representative immunostaining
micrographs show spatial distribution of M/M phenotype markers (CD11b, CD45, Ym1, CD206, CD68) into the ischemic area at 24 h after
ischemia (upper panels). Bar = 250 μm. Drawings representing the immunostaining data (lower panels). Only immunoreactivity for CD11b could
be observed outside the lesioned area in basal conditions (sham-operated mice). In the lesion, CD11b+ cells showing a ramified to globular
morphology could be observed going from the border zone to the ischemic core (red). CD45 staining was present throughout the entire
ischemic area (pink). Conversely CD68 appeared to be strongly concentrated in the border zone. Ym1 and CD206 were exclusively expressed in
the ischemic core.
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pMCAO
Twenty-four hours after ischemia CD68 was expressed in
hypertrophic ameboid CD11b cells present in the
ischemic core and in ramified microglia in the border
zone where CD68 positive cells were mostly located (Fig-
ure 4 and 5A-B). A similar pattern of coexpression could
be observed at 7d. At this time point the expression of
CD68 was greatly increased both in globular CD11b+
cells in the ischemic core and in ramified CD11b cells
laying in the border zone (Figure 4 and Figure 5C-D).
At 24 h after pMCAO Ym1 positive cells co-labeled
with CD11b globular cells within the ischemic core,
where they were exclusively located (Figure 4 and Figure
6A-B-E-F). Seven days after ischemia Ym1 and CD11b
Figure 5 Coexpression of CD11b (red) and CD68 (green) 24 h (A-B) and 7d (C-D) after pMCAO. In the ischemic core at 24 h CD11b
positive cells are prevalently globular and some of them are positive to CD68 (A). In the border zone (B) CD11b cells display rounded cell
bodies and ramified processes positive to CD68. Globular CD11b cells in the lesioned area 7d after ischemia mostly express CD68 marker (C). A
high number of CD11b cells displaying different morphology colabel with CD68 in the border zone (D). Data are representative of 3
independent experiments. Bars: 20 μm.
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(Figure 6C-D-G-H).
CD206 at 24 h was present exclusively in the ischemic
core (Figure 4) where it colocalized with globular
CD11b positive cells (Figure 7A-B-E-F). The same pat-
tern of coexpression was observed at 7d (Figure 7C-D-
G-H).
At 24 h after pMCAO, the few CD68+ cells found in
the ischemic core did not colocalize with Ym1+ cells
that were present exclusively in this area (Figure 4 and
Figure 8A-B). In the magnification of Figure 8E-F it is
possible to observe that even when these markers
appear closely related, they actually belong to distinct
cells. At longer times (7d) Ym1 cells not colocalizing
Figure 6 Coexpression of CD11b (red) and Ym1 (green) at 24 h (A-B-E-F) and 7d (C-D-G-H) after pMCAO. Ym1 positive cells co-label with
globular CD11b postive cells at both time points (A, C). High magnifications (E-G) and 3D rendering (F-H) show colabeling of markers further
highlighting the coexpression (blu = nuclei, bar: 5 μm). Consistent with the observation that no Ym1 cells are present in the border zone (Figure
4), no immunostaining for Ym1 at neither time points could be observed in this area (B, D). Data are representative of 3 independent
experiments. Bars: 20 μm.
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Page 9 of 19Figure 7 Coexpression of CD11b (red) and CD206 (green) at 24 h (A-B-E-F) and 7d (C-D-G-H) after pMCAO. At 24 h after ischemia some
globular CD11b cells co-label with CD206 marker in the ischemic core (A). Seven days after ischemia CD11b cells are prevalently globular in the
ischemic core and are highly positive to CD206 (C). High magnifications (E-G) and 3D rendering (F-H) show colabeling of markers further
highlighting the coexpression (blu = nuclei, bar: 5 μm). Consistent with the observation that no CD206 cells are present in the border zone
(Figure 4), no immunostaining for this marker at neither time points could be observed in this area (B, D). Data are representative of 3
independent experiments. Bars: 20 μm.
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CD68 can also be seen (Figure 8C-D-G-H).
A small fraction of CD206 positive cells show coex-
pression with CD68 at 24 h after ischemia in the
ischemic core (Figure 9A-E-F). Similar situation is
observed at 7d after pMCAO when a dramatic increase
in CD68 positive cells is apparent in the ischemic core
(Figure 9C-G-H). CD206 marker is not present in the
border zone at both time points (Figure 9B-D).
Ym1 and CD206 appeared to be coexpressed in the
ischemic core both at 24 h (Figure 10A-C-D) and 7d
(Figure 10B-E-F) after pMCAO. None of the two
Figure 8 Coexpression of CD68 (red) and Ym1 (green) at 24 h (A-B-E-F) and 7d (C-D-G-H) after pMCAO.A t2 4hC D 6 8p o s i t i v ec e l l s
found in the ischemic core do not co-localize with Ym1 positive cells (A). In high magnifications panels (E-F) the two markers appear to belong
to different cells although in close contact (blu = nuclei). Seven days after ischemia, when CD68 immunoreactivity is greately increased, Ym1
appears to be expressed also, but not exclusively in CD68 positive cells (C). Note the presence of one Ym1 positive cells (arrow) that does not
co-localize with CD68. High magnifications (G) and 3D rendering (H) show colabeling of markers further highlighting the coexpression (blu =
nuclei). Consistent with the observation that no Ym1 cells are present in the border zone (Figure 4), no immunoreactivity for this marker could
be observed at neither time points in that area (B, D). Data are representative of 3 independent experiments. Bars: 20 μm. High magnifications
and 3D rendering bar: 5 μm.
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Page 11 of 19Figure 9 Coexpression of CD68 (red) and CD206 (green) at 24 h (A-B-E-F) and 7d (C-D-G-H) after pMCAO. At 24 h and 7d after ischemia,
a minor part of CD68 positive cells found in the ischemic core colocalize with CD206 (A, C). High magnification (E-G) and 3D rendering (F-H)
show both single- and double-positive cells in the ischemic core (blu = nuclei, bar: 5 μm). Consistent with the observation that no CD206 cells
are present in the border zone (Figure 4), no immunoreactivity for this marker could be observed at neither time points in that area (B, D). Data
are representative of 3 independent experiments. Bars: 20 μm.
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Page 12 of 19markers was present in the border zone at both time
points considered (Figure 4).
As expected all CD11b globular, CD68 globular, Ym1
and CD206 positive cells were all positive for CD45
high
in both ischemic core and border zone (data not
shown), being CD45 a common marker for immune cell
populations [31,32].
A summary of M/M markers coexpression 24 h and
7d after the ischemic lesion is reported in Figure 11.
Lastly, to provide additional details on the functional
status of M/M, we assessed their relationship with neu-
rons (NeuN+). We analyzed CD11b/CD68 and CD11b/
Ym1 double positive cells as these populations showed
to increase at different time points, thus suggesting
Figure 10 Coexpression of Ym1 (red) and CD206 (green) at 24 h (A-C-D) and 7d (B-E-F) after pMCAO. At 24 h and 7d after ischemia Ym1
positive cells co-label with CD206 positive cells in the ischemic core (A-B) Bars: 20 μm. High magnification (C-E) and 3D rendering (D-F) show
coexpression of markers with the same cell nucleus (blu). Bar: 5 μm. Consistent with the observation that neither Ym1 cells nor CD206 cells are
present in the border zone (Figure 4) no immunostaining for these markers could be observed at neither time points in this area (data not
shown). Data are representative of 3 independent experiments.
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Page 13 of 19distinct functional states. CD11b stain of M/M mem-
branes was chosen for documenting the morphology of
M/M when contacting neurons. We found that neurons
were often enwrapped by CD11b positive cells in both
ischemic core and border zone at both 24 h and 7d
(Figure 12). In most cases CD11b cells surrounding
neurons were positive for CD68 at both zones (Figure
12A-B-C-D), suggesting an active phagocytosis. None of
the CD11b/Ym1 double positive cells at 24 h appeared
to be engaging a phagocytic interaction with neurons,
being these cells never in contact with NeuN positive
cells (Figure 12E). At 7d, a few CD11b/Ym1 double
Figure 11 Summary of M/M markers coexpression 24 h and 7d after the ischemic lesion. At 24 h after injury (A) immunoreactivity for
CD11, which is readly increased after ischemia, is expressed in ramified and globular cells. CD68 is present in a percentage of both globular and
ramified CD11b+ cells. Ym1 and CD206 that are present mostly in the core of the lesion, are expressed by a fraction of globular CD11b+ cells
and can be present on the same cells. A few cells coexpressing CD206 and CD68 can be found in the area between the core and the border
zone where the two markers are mainly located respectively. At 7d after injury (B) Ym1 decreases while CD68 expression greatly increases and
from the border zone where it was at earlier times it invades the ischemic core (see also data in Figure 3). A few CD68+ cells appear now to
express Ym1.
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Page 14 of 19positive cells showed a phagocytic appearance envelop-
ing neurons (Figure 12G), coherently with their partially
CD68 positive phenotype at this time point (Figure 8).
In the border zone, at both time points, Ym1 was not
detectable and only single CD11b positive cells did
envelop neurons (Figure 12F-H).
Discussion
Our study shows that the ischemic lesion is accompanied
by activation of specific M/M phenotype that presents
distinctive spatial and temporal features. We have
demonstrated that: 1) the ischemic lesion induces the
expression of the selected M/M markers that develop
over time, each with a specific pattern; 2) the selected
markers are associated with globular or ramified CD11b
morphology, 3) each marker has a given localization in
the lesioned area with no apparent major changes during
time, with the exception of CD68.
We have firstly determined the histopathological fea-
tures of the lesion induced by pMCAO. From the analysis
of the temporal evolution of the lesion it appears that the
percentage of neuronal loss is somehow stable from 24 h
up to 7d although the persistence of TUNEL-positive
cells at this late point indicates that some cells may still
be in degeneration at that late time. It should be noted
that assessing the lesion volume by the paleness of the
cresyl violet staining may lead to misleading conclusions
since, as detailed below, invading inflammatory cells may
contribute to the apparent reduction of the lesioned area
at 7d. Actually the quantification of the CD11b and
CD45
high immunoreactivity indicates that inflammatory
Figure 12 Coexpression of CD11b (red) and NeuN (blue) with CD68 (green) at 24 h (A-A’-B-B’) and 7d (C-C’-D-D’) or with Ym1 at 24 h
(E-E’-F-F’) and 7d (G-G’-H-H’) after pMCAO. In the ischemic core CD11b/CD68 double positive cells envelop NeuN positive cells, possibly
indicating phagocytosis of neurons (A; 3D rendering in A’). The same interaction was observed in the border zone (B-B’). At 7d after ischemia,
when CD68 expression is enhanced (Figure 3) in both ischemic core and border zone, CD11b/CD68 double positive cells enwrap neurons,
suggesting active phagocytosis also at this time point (C-C’-D-D’). At 24 h after pMCAO in the ischemic core, where Ym1 positive cells are
exclusively located, CD11b/Ym1 double positive cells do not appear involved in a phagocytic interaction with neurons (NeuN positive cells, E; 3D
rendering on E’). CD11b single positive cells in both ischemic core (E-E’) and border zone (where Ym1 is not expressed, F-F’) surround neurons.
At 7d after ischemia part of CD11b/Ym1 double positive cells engage a phagocytic appearance by enveloping neurons in ischemic core (G-G’)
coherently with their partially CD68 positive phenotype at this time point (Figure 8). In the border zone at 7d (Ym1 is absent) CD11b single
positive cells still enwrap neurons (H-H’). Data are representative of 3 independent experiments. Bar: 20 μm.
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Page 15 of 19cells rapidly increase in number and/or size early after
the injury and at every time point considered.
M/M play a pivotal role in surveillance and response to
altered CNS conditions [1,2,4]. An emerging concept is
that, similarly to what happens for peripheral macro-
phages, these cells can exert different antithetic functions
depending on environmental signals, acting as major
players in the pro-inflammatory cytotoxic response,
but also participating in the immunosuppressive and
self-repair processes [6,33,34]. The phenotype markers
considered in this study include classical markers of M/M
activation (CD11b and CD45) and markers expressed by
alternatively activated macrophages (CD68, Ym1 and
CD206). Although evidence of M2 activation state in the
brain has been reported in M/M in AD models [35,36],
following global ischemia [37], in models of experimental
autoimmune encephalomyelitis [38] or spinal cord injury
[16,39], information on M2 marker expression, coexpres-
sion and temporal evolution in the injuried brain is lack-
ing. We could observe that these phenotype markers are
exclusively expressed by CD11b cells and that each of
them shows distinct features in terms of time course of
activation and localization in relation to the ischemic
lesion.
CD11b is expressed on the surface of many leukocytes
and is a widely used maker of M/M. It belongs to a family
of cell surface receptors known as integrins. It is covalently
bound to a beta 2 subunit to form integrin aMb2 (Mac-1,
CD11b/CD18) which is implicated in diverse responses
including cell-mediated killing, phagocytosis, chemotaxis
and cellular activation. CD11b has the ability to recognize
a wide series of ligands such as fibrinogen, iC3b fragment
of the third complement component, ICAM-1, denatu-
rated products, blood coagulation factor X [40]. Our data
show that CD11b staining increases at early time points
after ischemia, rapidly reaching a plateau of activation.
Notably, CD11b positive cells display a different morphol-
ogy in relation to the lesion, namely they are ramified in
the border zone and ameboid in the ischemic core. Simi-
l a r l yt oC D 1 1 b ,a l s oC D 4 5
high cells increase rapidly after
ischemia. These cells, display a rounded morphology and
most probably correspond to recruited macrophages, neu-
trophils and lymphocytes [22,32,41]. This study does not
specifically address the question of differentiating between
invading macrophages and resident microglia. An impor-
tant future direction will be to identify specific molecular/
phenotypical markers for these two cell populations, since
there is evidence that they may play a different role in the
progression of brain injury [9,34,42].
CD68 or macrosialin is a member of the lysosomal/
endosomal-associated membrane glycoprotein (LAMP)
family and a member of the scavenger receptor family
which recognizes a wide range of anionic macromolecules
such as oxidatively modified lipoprotein, apoptotic cells
and cell surface antigens of microorganisms. Its localiza-
tion and predominance in phagocytic macrophages impli-
cates CD68 in phagocytosis [43,44]. We observed that the
early increase in CD68 immunoreactivity is concentrated
in the border zone and expressed in ramified CD11b posi-
tive cells. At later time points a dramatic increase in CD68
expression appears both in the border zone and the
ischemic core and is apparent in globular CD11b cells. At
both time points and in both zones, CD11b/CD68 double
positive cells appear to physically interact with neurons
and show a phagocytic-like morphology characterized by
neuron engulfment. The phagocytic activity of alterna-
tively activated M/M is associated to clearance of cells
debris, of damaged or dying cells and of infiltrating neu-
trophils thus resulting in the elimination of several poten-
tially cytotoxic substances [4,18,21,45,46]. However the
overall functional meaning of phagocytosis in acute brain
injury is still an open question. Actually the protective
effect of manipulations such as stem cell infusion may be
associated with a decrease in CD68 expression [47].
Ym1 belongs to the lectin family and is constitutively
expressed by liver, lung and bone marrow, consistently
with the fact that these are the original sources of myeloid
cells [48]. It is synthesized and secreted by activated
macrophages during inflammation and exhibits a pH-
dependent, specific activity towards GlcN oligomers and
heparin. Ym1 may control leukocyte trafficking by com-
peting with them for binding sites on local extracellular
matrix, an action resulting in down-regulation of inflam-
mation. Our findings show that, similarly to what reported
in peripheral macrophages, Ym1 is activated transiently
suggesting that it may be involved in the establishment of
an inflammatory management control of the injured
region [48]. Its expression is restricted to the ischemic
core and it colocalizes with CD11b globular cells and with
some CD68 cells at later times only. None of the CD11b/
Ym1 double positive cells is associated with phagocytosis
of neurons at 24 h, whilst at 7d some of them show a pha-
gocytic appearance and envelop neurons, coherently with
their partially CD68 positive phenotype at this time point.
An increase in Ym1 expression has been associated to the
beneficial effect of stem cell infusion in mice subjected to
global ischemia [37], in line with a protective role in acute
brain injury.
Another marker of alternatively activated macrophages is
CD206 or mannose receptor [45,49]. This is an endocytic
receptor that binds both microbial glycans and self glyco-
proteins carrying terminal mannose, fucose and N-acetyl-
glucosamine by interaction with its carbohydrate
recognition domains (CRDs). Its known function is related
to recognition and endocytosis of the carbohydrate portion
of antigens for processing and presentation [50]. Our
results show that CD206 expression significantly increases
over time and colocalizes with Ym1 positive cells and with
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Page 16 of 19a fraction of CD68 positive cells that increase at later time
points.
Lastly, our data have been obtained in a model of per-
manent ischemia and may not be extended to an ischemia
with reperfusion paradigm. Notably the present data and
our previous results [22] indicate that the ratio of
CD45
high/CD45
low is dramatically different in these two
conditions, being much higher after pMCAO. This may be
due to either a higher number of infiltrating cells and/or a
lower survival of resident cells, thus indicating that in tran-
sient ischemia the composition of the specific M/M popu-
lations in the lesioned area is different.
Conclusions
In the ischemic lesion M/M express markers that show
distinct temporal expression, distribution and association
with a definite cell morphology suggesting that different
M/M populations are acting at the site of injury according
to well defined phenotype, time of activation and pattern
of localization. Conceivably, at 24 h after insult, ramified
and phagocytic M/M surround the lesion, possibly acting
as a barrier against further expansion of the lesion, whilst
globular M/M committed to a protective phenotype (i.e.
expressing Ym1 and CD206) populate the ischemic core
with the primary function of resolving inflammation and
promoting wound healing. At later time points (7d) the
phagocytic behavior of M/M becomes prevalent in the
whole lesioned area with numerous globular phagocytic
M/M invading the core territory. The observed switch
towards the phagocytic phenotype is accompanied by the
progressive reduction of the expression of the protective
Ym1.
At 24 h protective Ym1 positive cells do not appear to
be involved in neuron phagocytosis, differently from
CD68 positive cells that show a close physical interac-
tion with neurons. At 7d, when neuronal damage
becomes irreversible in the core area, Ym1 positive cells
decrease and start to show phagocytic behavior being
partially co-localized with CD68. These cells now show
the ability to envelop neurons in a phagocytic-like man-
ner. Overall this effect suggests that endogenous protec-
tive mechanisms take place soon after injury (24 h-48 h)
and last at least up to 7d when phagocytosis of neurons
and debris removal are prevalent. Whether this effect is
beneficial or detrimental cannot be clearly established.
Phagocytosis (CD68 positive cells) can result in a pro-
tective function if properly balanced. In normal brain,
phagocytic function of microglia have been suggested to
support neurogenesis [51]. After an acute injury micro-
glia are supposed to remove cellular parts, as well as
whole cells [52], an action that might be necessary to
remove irreversibly damaged cells to make space for
new neuronal projections and fresh connections or
newly generated neurons.
The different states of M/M in the ischemic lesion
reflect the complexity of these cells and their ability to
differentiate towards a multitude of phenotypes depend-
ing on the surrounding microenvironmental signals that
can change over time. The inflammatory response that
follows cerebral ischemia is regarded as a promising tar-
get for stroke therapy. The data presented in this study
provide a basis for understanding this complex response
and for developing strategies resulting in promotion of a
protective inflammatory phenotype.
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